Global Liquid Biopsy Market is expected to reach $8,730.4 million by 2024; Finds New Report

Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

Liquid biopsy global market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.

The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.

The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.

The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.

The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of $1,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Spanning over 496 pages “Liquid Biopsy Global Market - Forecast to 2024” report covers Executive Summary, Introduction, Market Analysis, Market Sizing, Liquid Biopsy Global Market, By Biomarker, Liquid Biopsy Global Market, By Application, Liquid Biopsy Global Market, By Sample, Liquid Biopsy Global Market,  By End-Users, Regional Analysis, Competitive Landscape, Major Companies. This Report Covered 125 Companies Few Are - Bgi, Biocept, Inc., Caredx, Inc., Cynvenio Biosystems, Inc., Eurofins Scientific Se, Exact Sciences Corporation, Exosome Diagnostics, Guardant Health, Inc., Illumina, Inc., Immucor, Inc.

Please visit this link for more details: http://mrr.cm/Usa

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare